search
Back to results

Fructose in Exercising Individuals With Type 1 Diabetes Using Insulin Degludec (FruDeg)

Primary Purpose

Type 1 Diabetes Mellitus, Diabetes Complications

Status
Completed
Phase
Not Applicable
Locations
Switzerland
Study Type
Interventional
Intervention
Fructose
Plain water
Sponsored by
Insel Gruppe AG, University Hospital Bern
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for Type 1 Diabetes Mellitus focused on measuring Type 1 Diabetes, Fructose, Exercise, Hypoglycaemia, Degludec

Eligibility Criteria

18 Years - 45 Years (Adult)MaleDoes not accept healthy volunteers

Inclusion Criteria:

  • Type 1 diabetes as defined by the World Health Organization (WHO) for at least 1 year or confirmed negative C-peptide (<100pmol/l with concomitant blood glucose >4 mmol/l)
  • Male subjects aged between 18-45 years
  • HbA1c <8.0% (64mmol/mol) based on analysis from the central laboratory unit of the University Hospital Bern.
  • Basal/Bolus-insulin regimen with insulin degludec for at least 3 months, with good knowledge of insulin self-management
  • Regular physical activity (at least 30 min of moderate exercise 3 times weekly)
  • Written informed consent

Exclusion Criteria:

  • Relevant diabetic complications as judged by the investigator
  • Total daily insulin dose >2 IU/kg/day
  • Hypoglycaemia unawareness (Gold score > 4) or any episode of severe hypoglycaemia as defined by the American Diabetes Association within the last 6 months
  • Physical or psychological disease likely to interfere with the normal conduct of the study and interpretation of the study results as judged by the investigator
  • Current treatment with drugs known to interfere with metabolism, e.g. systemic corticosteroids, statins etc.
  • Known fructose-intolerance or malabsorption
  • Known allergy to one of the study drugs

Sites / Locations

  • Division of Endocrinology, Diabetes and Clinical Nutrition, Bern University Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Fructose in water first, water only second

Water only first, Fructose in water second

Arm Description

Intake of 20 g of fructose dissolved in 200 ml of tap water at first visit; intake of 200 ml of tap water at second visit

Intake of 200 ml of tap water at first visit; intake of 200 ml of 20 g of fructose dissolved in 200 ml of tap water at second visit

Outcomes

Primary Outcome Measures

Time (in minutes) to hypoglycaemia (plasma glucose <3.9mmol/l)
The development of hypoglycaemia will be determined by repeated measurement of plasma glucose.

Secondary Outcome Measures

Glucose levels before exercise
Plasma glucose will be measured repeatedly every 5 minutes
Glucose levels during exercise
Plasma glucose will be measured repeatedly every 5 minutes
Glucose levels after exercise
Plasma glucose will be measured repeatedly every 5 minutes
Lactate levels before exercise
Lactate will be measured repeatedly every 5 minutes
Lactate levels during exercise
Lactate will be measured repeatedly every 5 minutes
Lactate levels after exercise
Lactate will be measured repeatedly every 5 minutes
Insulin levels before exercise
Lactate will be measured repeatedly every 15 minutes
Insulin levels during exercise
Insulin will be measured repeatedly every 15 minutes
Insulin levels after exercise
Insulin will be measured repeatedly every 15 minutes
Heart rate before exercise
Heart rate will be measured using an electro-cardio-gramme
Heart rate during exercise
Heart rate will be measured using an electro-cardio-gramme
Oxygen consumption before exercise
Oxygen consumption will be measured via spirometry
Oxygen consumption during exercise
Oxygen consumption will be measured via spirometry
Carbon dioxide production before exercise
Carbon dioxide production will be measured via spirometry
Carbon dioxide production during exercise
Carbon dioxide production will be measured via spirometry

Full Information

First Posted
April 6, 2018
Last Updated
September 19, 2019
Sponsor
Insel Gruppe AG, University Hospital Bern
search

1. Study Identification

Unique Protocol Identification Number
NCT03497260
Brief Title
Fructose in Exercising Individuals With Type 1 Diabetes Using Insulin Degludec
Acronym
FruDeg
Official Title
Fructose to Reduce Exercise-associated Hypoglycaemia in Individuals With Type 1 Diabetes Treated With Insulin Degludec: Questioning a Paradigm and Offering a Novel Strategy
Study Type
Interventional

2. Study Status

Record Verification Date
September 2019
Overall Recruitment Status
Completed
Study Start Date
January 4, 2019 (Actual)
Primary Completion Date
September 6, 2019 (Actual)
Study Completion Date
September 8, 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Insel Gruppe AG, University Hospital Bern

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
To determine and compare the time-to-hypoglycaemia (defined as plasma glucose <3.9mmol/L) in individuals with type 1 diabetes treated with ultra-Long acting insulin degludec during aerobic exercise with or without prior ingestion of a single oral fructose load.
Detailed Description
Glycaemic control remains complex and demanding during exercise for type 1 diabetes (T1D) patients. Traditional treatment guidelines for exercise emphasizing the reduction of insulin doses and/or ingestion of additional carbohydrates are of limited applicability for patients treated with ultra-long acting basal insulin analogues. Dose reductions may require two to three days for modern basal insulin analogues in order to achieve an adapted steady state, hereby increasing the risk of inadequate insulin-following exercise. If T1D patients engage in recreational exercise - as recommended by every international treatment guideline - current treatment strategies may simply not be sufficient. As a consequence for patients treated with modern basal insulin analogues, it seems more adequate not to modify insulin doses but to apply alternative strategies for recreational exercise. The ingestion of fructose, an insulin-independent carbohydrate, which increases lipid oxidation but attenuates the dependency on carbohydrates may offer a novel strategy. Up to date, only preliminary data for fructose have been produced regarding clinical effectiveness and underlying mechanisms in the prevention of hypoglycaemia. The present comprehensive study aims to investigate the clinical efficacy, feasibility, and safety of a pre-exercise oral fructose load without modification of insulin degludec in T1D patients.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 1 Diabetes Mellitus, Diabetes Complications
Keywords
Type 1 Diabetes, Fructose, Exercise, Hypoglycaemia, Degludec

7. Study Design

Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
15 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Fructose in water first, water only second
Arm Type
Experimental
Arm Description
Intake of 20 g of fructose dissolved in 200 ml of tap water at first visit; intake of 200 ml of tap water at second visit
Arm Title
Water only first, Fructose in water second
Arm Type
Experimental
Arm Description
Intake of 200 ml of tap water at first visit; intake of 200 ml of 20 g of fructose dissolved in 200 ml of tap water at second visit
Intervention Type
Dietary Supplement
Intervention Name(s)
Fructose
Intervention Description
Intake of 20 g of fructose dissolved in 200 ml of tap water within 5 minutes 30 minutes prior to exercise.
Intervention Type
Other
Intervention Name(s)
Plain water
Intervention Description
Intake of 200 ml of tap water within 5 minutes 30 minutes prior to exercise.
Primary Outcome Measure Information:
Title
Time (in minutes) to hypoglycaemia (plasma glucose <3.9mmol/l)
Description
The development of hypoglycaemia will be determined by repeated measurement of plasma glucose.
Time Frame
From time point 0 minutes (initiation of exercise) to time point 60 minutes (completion of exercise) or development of hypoglycaemia
Secondary Outcome Measure Information:
Title
Glucose levels before exercise
Description
Plasma glucose will be measured repeatedly every 5 minutes
Time Frame
Time point -30 minutes until time point 0 minutes (initiation of exercise)
Title
Glucose levels during exercise
Description
Plasma glucose will be measured repeatedly every 5 minutes
Time Frame
From time point 0 minutes until time point 60 minutes (completion of exercise) or development of hypoglycaemia
Title
Glucose levels after exercise
Description
Plasma glucose will be measured repeatedly every 5 minutes
Time Frame
From time point 0 minutes until time point 90 minutes
Title
Lactate levels before exercise
Description
Lactate will be measured repeatedly every 5 minutes
Time Frame
From time point -30 minutes until time point 0 minutes (initiation of exercise)
Title
Lactate levels during exercise
Description
Lactate will be measured repeatedly every 5 minutes
Time Frame
From time point 0 minutes until time point 60 minutes (completion of exercise) or development of hypoglycaemia
Title
Lactate levels after exercise
Description
Lactate will be measured repeatedly every 5 minutes
Time Frame
From time point 0 minutes until time point 90 minutes
Title
Insulin levels before exercise
Description
Lactate will be measured repeatedly every 15 minutes
Time Frame
Time point -30 minutes until time point 0 minutes (initiation of exercise)
Title
Insulin levels during exercise
Description
Insulin will be measured repeatedly every 15 minutes
Time Frame
From time point 0 minutes until time point 60 minutes (completion of exercise) or development of hypoglycaemia
Title
Insulin levels after exercise
Description
Insulin will be measured repeatedly every 15 minutes
Time Frame
From time point 0 minutes until time point 150 minutes
Title
Heart rate before exercise
Description
Heart rate will be measured using an electro-cardio-gramme
Time Frame
Time point -30 minutes until time point 0 minutes (initiation of exercise)
Title
Heart rate during exercise
Description
Heart rate will be measured using an electro-cardio-gramme
Time Frame
From time point 0 minutes until time point 60 minutes (completion of exercise) or development of hypoglycaemia
Title
Oxygen consumption before exercise
Description
Oxygen consumption will be measured via spirometry
Time Frame
Between 15 minutes and 5 minutes before initiation of exercise
Title
Oxygen consumption during exercise
Description
Oxygen consumption will be measured via spirometry
Time Frame
Between 15 minutes and 20 minutes during exercise
Title
Carbon dioxide production before exercise
Description
Carbon dioxide production will be measured via spirometry
Time Frame
Between 15 minutes and 5 minutes before initiation of exercise
Title
Carbon dioxide production during exercise
Description
Carbon dioxide production will be measured via spirometry
Time Frame
Between 15 minutes and 20 minutes during exercise

10. Eligibility

Sex
Male
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Type 1 diabetes as defined by the World Health Organization (WHO) for at least 1 year or confirmed negative C-peptide (<100pmol/l with concomitant blood glucose >4 mmol/l) Male subjects aged between 18-45 years HbA1c <8.0% (64mmol/mol) based on analysis from the central laboratory unit of the University Hospital Bern. Basal/Bolus-insulin regimen with insulin degludec for at least 3 months, with good knowledge of insulin self-management Regular physical activity (at least 30 min of moderate exercise 3 times weekly) Written informed consent Exclusion Criteria: Relevant diabetic complications as judged by the investigator Total daily insulin dose >2 IU/kg/day Hypoglycaemia unawareness (Gold score > 4) or any episode of severe hypoglycaemia as defined by the American Diabetes Association within the last 6 months Physical or psychological disease likely to interfere with the normal conduct of the study and interpretation of the study results as judged by the investigator Current treatment with drugs known to interfere with metabolism, e.g. systemic corticosteroids, statins etc. Known fructose-intolerance or malabsorption Known allergy to one of the study drugs
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Christoph Stettler, MD
Organizational Affiliation
Inselspital, Bern University Hospital, University of Bern
Official's Role
Principal Investigator
Facility Information:
Facility Name
Division of Endocrinology, Diabetes and Clinical Nutrition, Bern University Hospital
City
Bern
ZIP/Postal Code
3010
Country
Switzerland

12. IPD Sharing Statement

Plan to Share IPD
Undecided
Citations:
PubMed Identifier
32591421
Citation
Kosinski C, Herzig D, Laesser CI, Nakas CT, Melmer A, Vogt A, Vogt B, Laimer M, Bally L, Stettler C. A Single Load of Fructose Attenuates the Risk of Exercise-Induced Hypoglycemia in Adults With Type 1 Diabetes on Ultra-Long-Acting Basal Insulin: A Randomized, Open-Label, Crossover Proof-of-Principle Study. Diabetes Care. 2020 Sep;43(9):2010-2016. doi: 10.2337/dc19-2250. Epub 2020 Jun 26.
Results Reference
derived

Learn more about this trial

Fructose in Exercising Individuals With Type 1 Diabetes Using Insulin Degludec

We'll reach out to this number within 24 hrs